Corona Remedies IPO: Key Details and Subscription Status
The initial public offering (IPO) of Corona Remedies Ltd, a prominent pharmaceutical company, opened for subscription on December 8, 2025. This IPO is significant for investors in India, particularly given the company's focus on critical healthcare areas such as women's health, cardiology, pain management, and urology.
The price band for the Corona Remedies IPO is set between ₹1,008 and ₹1,062 per share. At the upper end of this band, the company aims to raise ₹655.37 crore through an offer for sale of approximately 61.71 lakh equity shares. This means that the IPO provides a considerable opportunity for investors looking to be part of a growing sector.
As the IPO opened, it received a warm reception in the market, with a strong grey market premium (GMP) of ₹290 per share, indicating that shares are trading at ₹1,352 in the grey market. This represents a notable 27.31% premium over the upper issue price, suggesting that investor sentiment is positive.
The minimum investment required by retail investors is ₹14,868, which allows them to purchase a lot size of 14 shares. This accessibility is likely to encourage participation among a broader range of investors, especially those looking to diversify their portfolios in the pharmaceutical sector.
As of the first day of bidding, the IPO has been subscribed 16%, with retail investors showing a 24% subscription rate. In contrast, non-institutional investors have contributed 18%. Qualified Institutional Buyers (QIBs) have yet to make their bids, and their participation is often crucial in determining the overall success of an IPO.
It’s important to note that this IPO is entirely an offer for sale, meaning that the company will not receive any funds from this issue; all proceeds will go to selling shareholders, which include the company’s promoters and other investors. The allotment date for the IPO is expected to be December 11, and shares are anticipated to be listed on both BSE and NSE on December 15.
In summary, the Corona Remedies IPO presents a compelling opportunity for investors in India, especially given the strong demand seen in the grey market. Investors should stay informed and consider their options carefully as the subscription period progresses.
